Activity of a mycobacterial antineoplastic glycan against human breast cancer

Anticancer Research

Volumn 17, Issue 1 A, 1997, Pages 445-450

  Donmez, Cigdem ^a   Groves, Michael J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antineoplastic activity; Breast cancer; Mycobacterial glycan

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; ESTRADIOL; FLUOROURACIL; GLYCAN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MACROPHAGE; MOUSE; MYCOBACTERIUM BOVIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MICE; MYCOBACTERIUM BOVIS; POLYSACCHARIDES; TUMOR CELLS, CULTURED;

EID: 0031055879     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Pearle R: Cancer and tuberculosis. J Hyg 2: 97-159, 1929.
2. Rosenthal SR: 'BCG Vaccine: Tuberculosis-Cancer', PSG Publishing, Littleton, MA, 1980.
3. Groves MJ: Pharmaceutical characterization of Mycobacterium bovis Bacillus Calmette Guérin (BCG) vaccine used for the treatment of superficial bladder cancer. J Pharm Sci 82: 555-562, 1993.
4. Suzuki I, Kuranobu M, Matsumura A, Kushida H: Effect of SSM, an extract from human type tubercle bacilli on the granulopectic activity of the reticuloendothelial system II. Activation of the carbon-phagocytic functions and its dose response. Pharmacometrics 16: 79-85, 1978.
5. 14C-labeling of hematopoietic immunomodulator (Z-100) consisting of polysaccharides obtained from cultivation of Mycobacterium tuberculosis. J Labelled Compounds Radiopharm 29: 131-142, 1991.
6. Fujita K, Hirai T, Maruyama C, Ogawa H and Yoshio I: A case of metastatic lung cancer healed clinically with an extract from the tubercle bacilli (Maruyama vaccine - SSM), Cancer Detect. Prevent 4: 337-346, 1981.
7. Sasaki H, Schmitt D, Hayashi Y, Pollard RB and Suzuki F: Induction of interleukin 3 and tumor resistance by SSM, a cancer immunotherapeutic agent extracted from Mycobacterium tuberculosis, Cancer Res 50: 4032-4037, 1990.
8. Luo Y, Klegerman ME, Muhammad A, Dai X and Groves MJ: Initial characterization of an antineoplastic polysaccharide-rich extract of Mycobacterium bovis BCG, Tice® substrain, Anticancer Res 14: 1469-1476, 1994.
9. Wang R, Klegerman ME, Marsden I, Sinnott M and Groves MJ: An antineoplastic glycan isolated from Mycobacterium bovis BCG vaccine. Biochem J 311: 867-872, 1995.
10. Groves MJ, Klegerman ME, Ciftci KC and Tian X: Isolation, characterization and formulation of an antineoplastic glycan from cultures of Mycobacterium vaccae. J Pharm Pharmacol 47: 12B, 1995.
11. Rajala P, Kaasmen E, Rintala E, Jauhiainen K, Nurmi M, Alfthan O and Lähde M: Cytostatic effect of different strains of Bacillus Calmette Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-α. Urol Res 20: 215-217, 1992.
12. Devadoss PO, Klegerman ME and Groves MJ: Phagocytosis of Mycobacterium bovis BCG organisms by murine S180 sarcoma cells. Cytobios 74: 49-58, 1993.
13. Heise ER, Myrnk ON and Leake ES: Effect of Bacillus Calmette Guérin on the levels of acid phosphatase. lysozyme and cathepsin in rabbit alveolar macrophages. J Immunol 95: 125-128, 1965.
14. Hibbs JB, Taintor RR, Chapman HA and Weinberg JB: Macrophage tumor killing: influence of the local environment. Science 197: 279-281, 1977.
15. Nathan CF, Brukner LU, Silverstein SC and Cohn ZA: Extracellular Cytolysis by activated macrophages and granulocytes. I. Pharmacologic triggering of effector cells and the release of hydrogen peroxide. J Exp Med 149: 84-87, 1976.
16. Friess W, Zhou W and Groves MJ: In vivo activity of collagen matrices containing PS1, an antineoplastic glycan against murine sarcoma cells. Pharm Sci 2(3): 121-124, 1996.
17. Klegerman ME, Muhammad AS and Groves MJ: Efficacy of an antineoplastic BCG glycolipid extract (PS1) against the MB49 mouse bladder carcinoma in vivo. Pharm Res 11(10): S-94, 1994.
18. Miller BA, Feuer EJ and Hanley BF: Incidence of breast cancer has risen dramatically since 1982, C.A.J. Clin 43: 27-41, 1993.
19. Carlson R and Stockdale F: The clinical biology of breast cancer. Ann Rev Med 39: 455-464, 1988.
20. Klegerman ME, Ujjainwala L and Zeunert PL: High-dose inhibition and low-dose enhancement of murine sarcoma growth exhibited by BCG vaccine. Cancer Letters 56: 137-145, 1991.
21. Osborne KC, Coronado EB and Robinson JP: Human breast cancer in the athymic nude mouse, Europ J Cancer Clin Oncol 23(8): 1189-1196, 1987.
22. Teh M and Hui KM: Modulation of MHC gene expression in human breast carcinoma cells by hormones. J Immunogenetics 16: 397-405, 1989.
23. Rodriguez F, Peran F, Garrido F and Ruiz-Cabello F: Upmodulation by estrogen of HLA class 1 expression in breast tumor cell lines. Immunogenetics 39: 161-167, 1994.
24. van Netten JP, Ashmead BJ, Parker RL, Thornton IG, Fletcher C, Cavers D, Coy P and Brigden ML: Macrophage-tumor cell associations: a factor in metastasis breast cancer? J Leukocyte Biol 54: 360-362, 1993.
25. van Netten JP, Ashmead BJ, Cavers D, Fletcher C, Thornton IG, Antonson BL, Coy P and Brigden ML: 'Macrophages' and their putative significance in human breast cancer. Brit J Cancer 66: 220-221, 1992.